Real-time liquid biopsy in cancer patients: fact or fiction?
Standard
Real-time liquid biopsy in cancer patients: fact or fiction? / Pantel, Klaus; Alix-Panabières, Catherine.
In: CANCER RES, Vol. 73, No. 21, 01.11.2013, p. 6384-8.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Real-time liquid biopsy in cancer patients: fact or fiction?
AU - Pantel, Klaus
AU - Alix-Panabières, Catherine
PY - 2013/11/1
Y1 - 2013/11/1
N2 - Distant metastases harbor unique genomic characteristics not detectable in the corresponding primary tumor of the same patient and metastases located at different sites show a considerable intrapatient heterogeneity. Thus, the mere analysis of the resected primary tumor alone (current standard practice in oncology) or, if possible, even reevaluation of tumor characteristics based on the biopsy of the most accessible metastasis may not reveal sufficient information for treatment decisions. Here, we propose that this dilemma can be solved by a new diagnostic concept: liquid biopsy, that is, analysis of therapeutic targets and drug resistance-conferring gene mutations on circulating tumor cells (CTC) and cell-free circulating tumor DNA (ctDNA) released into the peripheral blood from metastatic deposits. We discuss the current challenges and future perspectives of CTCs and ctDNA as biomarkers in clinical oncology. Both CTCs and ctDNA are interesting complementary technologies that can be used in parallel in future trials assessing new drugs or drug combinations. We postulate that the liquid biopsy concept will contribute to a better understanding and clinical management of drug resistance in patients with cancer.
AB - Distant metastases harbor unique genomic characteristics not detectable in the corresponding primary tumor of the same patient and metastases located at different sites show a considerable intrapatient heterogeneity. Thus, the mere analysis of the resected primary tumor alone (current standard practice in oncology) or, if possible, even reevaluation of tumor characteristics based on the biopsy of the most accessible metastasis may not reveal sufficient information for treatment decisions. Here, we propose that this dilemma can be solved by a new diagnostic concept: liquid biopsy, that is, analysis of therapeutic targets and drug resistance-conferring gene mutations on circulating tumor cells (CTC) and cell-free circulating tumor DNA (ctDNA) released into the peripheral blood from metastatic deposits. We discuss the current challenges and future perspectives of CTCs and ctDNA as biomarkers in clinical oncology. Both CTCs and ctDNA are interesting complementary technologies that can be used in parallel in future trials assessing new drugs or drug combinations. We postulate that the liquid biopsy concept will contribute to a better understanding and clinical management of drug resistance in patients with cancer.
KW - DNA, Neoplasm
KW - Humans
KW - Neoplasms
KW - Neoplastic Cells, Circulating
KW - Tumor Markers, Biological
U2 - 10.1158/0008-5472.CAN-13-2030
DO - 10.1158/0008-5472.CAN-13-2030
M3 - SCORING: Journal article
C2 - 24145355
VL - 73
SP - 6384
EP - 6388
JO - CANCER RES
JF - CANCER RES
SN - 0008-5472
IS - 21
ER -